<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099757</url>
  </required_header>
  <id_info>
    <org_study_id>DXSHB20211012</org_study_id>
    <nct_id>NCT05099757</nct_id>
  </id_info>
  <brief_title>The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students</brief_title>
  <official_title>The Study on the Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-HBs produced after hepatitis B vaccination will decrease over time. College students&#xD;
      are vaccinated with hepatitis B vaccine at birth, and their antibodies may have decreased&#xD;
      significantly. In addition, college students are sexually active population, which has a high&#xD;
      risk of HBV infection. It is necessary to study the anti-HBs level of college students, and&#xD;
      analyze the strengthening immunization for this special group.&#xD;
&#xD;
      This study will analyze the immunogenicity, immune persistence, and safety of booster dose of&#xD;
      intramuscular 20 µg recombinant hepatitis B vaccines. Different booster vaccination including&#xD;
      one-dose (0 month), two-dose (0, 1 months), or three-dose (0, 1, and 6 months) was given&#xD;
      according to the antibody production level after booster vaccination among college students.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are given booster dose of one-dose (0 month), two-dose (0, 1 months), or&#xD;
      three-dose (0, 1, and 6 months) 20 µg recombinant hepatitis B vaccine according to the&#xD;
      antibody production level. HBsAg and anti-HBs will be tested during the study period. Adverse&#xD;
      reactions will be recorded after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 1</measure>
    <time_frame>Months 1</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 3</measure>
    <time_frame>Months 3</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 7</measure>
    <time_frame>Months 7</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 12</measure>
    <time_frame>Months 12</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 18</measure>
    <time_frame>Months 18</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 24</measure>
    <time_frame>Months 24</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs Seroconversion Rate at Months 30</measure>
    <time_frame>Months 30</time_frame>
    <description>Anti-HBs Seroconversion Rate at Months 30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 1</measure>
    <time_frame>Months 1</time_frame>
    <description>Anti-HBs Concentration at Months 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 3</measure>
    <time_frame>Months 3</time_frame>
    <description>Anti-HBs Concentration at Months 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 7</measure>
    <time_frame>Months 7</time_frame>
    <description>Anti-HBs Concentration at Months 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 12</measure>
    <time_frame>Months 12</time_frame>
    <description>Anti-HBs Concentration at Months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 18</measure>
    <time_frame>Months 18</time_frame>
    <description>Anti-HBs Concentration at Months 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 24</measure>
    <time_frame>Months 24</time_frame>
    <description>Anti-HBs Concentration at Months 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Months 30</measure>
    <time_frame>Months 30</time_frame>
    <description>Anti-HBs Concentration at Months 30</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of Adverse Events After Vaccination</measure>
    <time_frame>Within 7 days after the vaccination</time_frame>
    <description>Occurrence of Adverse Events After Vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of Adverse Events After Vaccination</measure>
    <time_frame>Within 28 days after vaccination</time_frame>
    <description>Occurrence of Adverse Events After Vaccination</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B Vaccine</condition>
  <arm_group>
    <arm_group_label>20 µg at month 0, months 0, 1 or 0, 1, and 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 µg recombinant hepatitis B vaccine with one, two or three injections at month 0, months 0, 1 or 0, 1, and 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20 µg dose hepatitis B vaccine</intervention_name>
    <description>one-dose, two-dose or three-dose, 20 µg per dose</description>
    <arm_group_label>20 µg at month 0, months 0, 1 or 0, 1, and 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged of 18 years or above&#xD;
&#xD;
          -  Serologically negative for hepatitis B surface antigen (HBsAg), hepatitis B surface&#xD;
             antibody (anti-HBs) at enrollment&#xD;
&#xD;
          -  Sign informed consent, willing to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being pregnant&#xD;
&#xD;
          -  Intolerance or allergy to any component of the vaccine&#xD;
&#xD;
          -  Participants with severe acute or chronic diseases (such as liver disease, blood&#xD;
             disease, cancer), acute onset of chronic diseases and fever&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suping Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suping Wang, PhD</last_name>
    <phone>+86-351-4135103</phone>
    <email>supingwang@sxmu.edu.cn</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Suping Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Booster Dose</keyword>
  <keyword>Long-term Immune Response</keyword>
  <keyword>College Students</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

